MUFG Americas’s NovoCure NVCR Stock Holding History

MUFG Americas’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-916	Closed	-$7K	–	1169
2016 Q4	$7K	Buy	916 +105	+13%	+$845	﹤0.01%	904
2016 Q3	$7K	Hold	811	–	–	﹤0.01%	923
2016 Q2	$9K	Buy	+811	New	+$10.2K	﹤0.01%	879

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

MUFG Americas's NVCR Position: Q1 2017 in Review

MUFG Americas sold out of NovoCure (NVCR) in Q1 2017, closing a stake of 916 shares — an estimated $7K sold.

MUFG Americas first reported a position in NVCR in Q2 2016 and held it in 3 quarters. The position peaked at $9K in Q2 2016. 71 funds tracked by Wall St. Rank hold NVCR as of Q1 2017.

MUFG Americas reported no remaining NovoCure position as of Q1 2017 after selling out during the quarter.
MUFG Americas sold 916 NovoCure shares in Q1 2017, an estimated $7K.
MUFG Americas first reported a position in NovoCure in Q2 2016 and held it in 3 quarters.
MUFG Americas's NovoCure position peaked at $9K in Q2 2016.
71 funds tracked by Wall St. Rank held NovoCure as of Q1 2017.

Based on MUFG Americas's 13F filing for Q1 2017, filed 4 May 2017.